Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
Date:6/6/2009

- Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results -

NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the American Diabetes Association's 69th Scientific Sessions. Lorcaserin patients achieved highly significant categorical and absolute weight loss in Year 1, and continued treatment with lorcaserin in Year 2 helped significantly more patients maintain their weight loss as compared to those on placebo. Treatment with lorcaserin also resulted in highly significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin did not result in increased risk of depression and was not associated with the development of cardiac valvular insufficiency.

Previously announced BLOOM data demonstrated that lorcaserin was highly efficacious, achieving statistical significance on all three co-primary efficacy endpoints, and was very well tolerated. The BLOOM results also satisfy the efficacy requirement in the most recent US Food and Drug Administration, or FDA, draft guidance for the development of drugs for weight management.

"These data provide reason for new optimism for the millions of people who struggle with managing their weight and are in need of novel, well tolerated treatments to help improve their overall health," said Steven R. Smith, M.D., Co-Principal Investigator and Professor and Assistant Director for Clinical Research at
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
2. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Critical Pharmaceuticals Enter Sustained Release hGH Arena
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... H1 2015" therapeutic market research report of 52 ... its online business intelligence library. The ... information on the therapeutic development for Visceral Pain, ... assessment by drug target, mechanism of action (MoA), ...
(Date:3/26/2015)... -- The Burzynski Research Institute, Inc. (BRI) announced today that ... Department of Surgery at Kurume University Medical Center ... published. The study, a randomized non-blinded phase 2 ... adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections ... A total of 65 patients, with histologically ...
(Date:3/26/2015)... Columbia, March 26, 2015  OncoGenex Pharmaceuticals, Inc. ... of clinical developments and announced fourth quarter and ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... agreed to negotiate the termination of their collaboration ... the final termination agreement are ongoing. , ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... High-dose ursodeoxycholic acid detrimental for treatment of primary sclerosing ... A national team of researchers led by scientists at Mayo Clinic ... chronic liver disease, is not helpful for patients, according to a ... . , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090105/MAYOLOGO ...
... , , , ZURICH, ... ) scientists have been able to image the "anatomy" -- or chemical structure ... noncontact atomic force microscopy . , , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ) , , The ...
Cached Medicine Technology:Researchers Find High-Dose Therapy for Liver Disease Not Effective 2Researchers Find High-Dose Therapy for Liver Disease Not Effective 3Researchers Find High-Dose Therapy for Liver Disease Not Effective 4IBM Scientists First to Image the 'Anatomy' of a Molecule 2IBM Scientists First to Image the 'Anatomy' of a Molecule 3IBM Scientists First to Image the 'Anatomy' of a Molecule 4IBM Scientists First to Image the 'Anatomy' of a Molecule 5
(Date:3/27/2015)... Mirada, CA (PRWEB) March 27, 2015 ... physician, Stanley G. Katz, M.D., is now treating knee ... California, including Anaheim , Long Beach, and La ... treatment of acute knee and hip joint disorders as ... Stanley Katz is passionate in returning his patients back ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
(Date:3/27/2015)... 2015 On March 19, 2015, ... Detroit Lions wide receiver Herman Moore, hosted “Fighting ... on substance abuse, treatment options and the recent ... were pastors, ministers and bishops from local churches ... guests. , “Our ‘Fighting Addiction Together’ luncheon was ...
(Date:3/27/2015)... FL and London, UK (PRWEB) March 27, 2015 ... announced today that it has appointed Sean Fitzgerald, a ... role of Chief Operating Officer and Interim Chief Financial ... President of leading education technology innovator, EverFi, backed by ... Schmidt, and Twitter founder Evan Williams. Prior to EverFi, ...
(Date:3/27/2015)... WA (PRWEB) March 27, 2015 When ... can be hard to know where to begin. The ... experienced Seattle trucking accident attorney, offers accident victims a ... and legal assistance to ensure their personal injury claim ... begins by describing the first actions that should be ...
Breaking Medicine News(10 mins):Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , TUESDAY, Nov. 16 (HealthDay News) -- Men who ... disease, new research suggests. The notion is based on ... a thickening of the men,s neck,s carotid artery wall. Such ... for heart disease. What,s more, the link between sleep ...
... TUESDAY, Nov. 16 (HealthDay News) -- A rare, but ... hyperemesis gravidarum, may be hereditary, researchers say. Each ... are hospitalized due to hyperemesis gravidarum (HG), marked by ... cause weight loss, dehydration and psychological trauma. The condition, ...
... , TUESDAY, Nov. 16 (HealthDay News) -- Bouts ... behavior over time, including their propensity for more heavy drinking, ... 500 boys in Pittsburgh who were assessed each year from ... four to five years later. When they were teens, ...
... Three-year-old Denver resident Brianna,s favorite color was yellow and her ... At 18 months she strapped on her first pair of ... loved playing with her brother and noticed everything. ... from a cardiac arrhythmia known as Long QT Syndrome. Brianna,s ...
... N.C. The National Institutes of Health (NIH), National ... Duke University Medical Center up to $52.8 million over ... and oversight of external quality assurance programs that monitor ... around the world. The project, External Quality ...
... Nov. 16 (HealthDay News) -- Hospital care-related problems contribute ... month, according to a new federal government study. ... including infections, bed sores and excessive bleeding from blood-thinning ... patients discharged from hospitals in October 2008, USA ...
Cached Medicine News:Health News:Shorter Sleep in Men Ups Risk of Heart Disease: Study 2Health News:Rare, Severe Form of Morning Sickness Appears to Be Genetic 2Health News:For Teen Boys, Heavy Drinking & Impulsivity May Be Vicious Circle 2Health News:University of Colorado in pilot project to map defibrillators 2Health News:Duke to lead oversight of HIV laboratories worldwide 2Health News:Duke to lead oversight of HIV laboratories worldwide 3Health News:Hospital Care Deadly for Some, U.S. Study Finds 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 0.5-10 microliter range....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Medicine Products: